Allscripts Healthcare Solutions - MDRX Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allscripts Healthcare Solutions in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1-year price objectives for Allscripts Healthcare Solutions' stock. Their MDRX share price forecasts range from $17.00 to $26.00. On average, they anticipate the company's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for MDRX or view top-rated stocks among Wall Street analysts.

Allscripts Healthcare Solutions' stock was trading at $18.45 on January 1st, 2022. Since then, MDRX shares have decreased by 17.5% and is now trading at $15.23.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MDRX earnings forecast.

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) released its quarterly earnings results on Thursday, August, 4th. The software maker reported $0.18 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.03. The software maker earned $150.90 million during the quarter, compared to analysts' expectations of $148.58 million. Allscripts Healthcare Solutions had a net margin of 5.90% and a trailing twelve-month return on equity of 10.62%. The business's revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.17 earnings per share.

Allscripts Healthcare Solutions announced that its Board of Directors has authorized a share repurchase program on Wednesday, May 26th 2021, which permits the company to buyback $350,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 14% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

796 employees have rated Allscripts Healthcare Solutions Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allscripts Healthcare Solutions investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

Allscripts Healthcare Solutions trades on the NASDAQ under the ticker symbol "MDRX."

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDRX stock can currently be purchased for approximately $15.23.

Allscripts Healthcare Solutions (NASDAQ:MDRX) has a market capitalization of $1.69 billion and generates $1.50 billion in revenue each year. The software maker earns $134.44 million in net income (profit) each year or $0.43 on an earnings per share basis.

The company employs 8,000 workers across the globe.

Allscripts Healthcare Solutions' mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The official website for the company is www.allscripts.com. The software maker can be reached via phone at (800) 334-8534, via email at stephen.shulstein@allscripts.com, or via fax at 313-322-9600.